Recently, Novocure announced that its clinical phase 3 key EF-14 trial results show that the use of the headset Optune in combination with temozolomide in the treatment of newly diagnosed glioblastoma (GBM), the patient's survival has been significantly extended.
Glioblastoma is the most common malignant tumor in the brain and the most aggressive brain tumor. Survival rates are still very low even for patients undergoing surgery and high-dose radiation therapy. This tumor grows rapidly and has an average survival of 12 to 18 months. Only 20% of patients survived for more than a year, and only 3% of patients who survived for more than 3 years. Therefore, patients suffering from this disease are also in desperate need of a new treatment.
Optune is a portable, wearable and FDA approved device. It safely delivers continuous treatment to the brain area where the GBM tumor is located. As a clinical device, how does it help treat GBM?
When cells undergo cancer, they divide rapidly and are uncontrollable. This produces more and more cancer cells that form a mass, called a tumor. When Optune is working, a low-intensity electric field (TTField) called a tumor treatment field is formed, which helps to slow or prevent the division of glioblastoma cancer cells, and may also cause cancer cells to die. Because TTFields don't enter the bloodstream like drugs, they don't affect cells in other parts of the body. The most common (≥10%) adverse reaction when using Optune alone is scalp irritation and headache caused by the use of the device.
EF-14 data showed that patients receiving a combination of Optune and temozolomide had a median survival of nearly 5 months compared with those treated with temozolomide alone. According to five consecutive years of monitoring, patients treated with Optune in combination with temozolomide maintained a higher survival rate than patients treated with temozolomide alone. The 5-year survival rate was 13% in patients receiving Optune and temozolomide, compared with 5% in patients treated with temozolomide alone. The data also showed that patients treated with Optune were able to maintain a better quality of life than patients treated with temozolomide alone.
The EF-14 data also showed that Optune and temozolomide did not have a negative impact on health-related quality of life except for itchy skin. The combination treatment of Optune and temozolomide improves several pre-defined, health-related, disease-free survival with quality of life levels compared to treatment with temozolomide alone.
Dr. Eilon Kirson, Chief Scientific Officer and Head of Research and Development at Novocure, said: "As the first treatment to improve the survival of newly diagnosed GBM patients in 10 years, Optune has been shown to significantly improve the quality of life of patients with GBM."
Original title: Extending the survival period for nearly half a year, the magic "hat" to help malignant brain tumor treatment
Teach you to use APP (Pharmaceutical Pass) to seize business opportunities
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients(API) refer to the raw materials used in the production of various preparations. They are the effective ingredients in the preparations. They are various powders, crystals, extracts, etc., prepared by chemical synthesis, plant extraction or biotechnology, but Substances that the patient cannot take directly. API is intended to be used in any substance or mixture of substances in the manufacture of pharmaceuticals, and when used in pharmaceuticals, it becomes an active ingredient of the pharmaceuticals. Such substances have pharmacological activity or other direct effects in the diagnosis, treatment, symptom relief, treatment or prevention of diseases, or can affect the function or structure of the body. According to its source, active pharmaceutical ingredients are divided into two categories: synthetic chemical active Pharmaceutical ingredients and natural chemical active Pharmaceutical ingredients.
Chromium Picolinate,Tianeptine,6-Paradol,Aminobutyric acid,acetylcysteine,L-Carnosine
Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualyn-bio.com